Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 11/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765655 | 0.94 | AVPR1B (0.36) | AVPR1BF2NTRK1CMA1ELANE | |
| SCHEMBL30765577 | 0.90 | AVPR1B (0.36) | AVPR1BF2NTRK1CMA1ELANE | |
| SCHEMBL30765562 | 0.88 | F2 (0.36) | AVPR1BF2CMA1ELANECASP1 | |
| SCHEMBL30765634 | 0.84 | CASP1 (0.42) | AVPR1BNTRK1CMA1ELANECASP1 | |
| SCHEMBL30765946 | 0.84 | F2 (0.39) | F2 | |
| SCHEMBL30765437 | 0.82 | HDAC6 (0.41) | F2CMA1ELANECTRC | |
| SCHEMBL30766049 | 0.82 | NTRK1 (0.43) | AVPR1BF2NTRK1CMA1ELANE | |
| SCHEMBL30765470 | 0.81 | AVPR1B (0.37) | AVPR1BF2NTRK1CMA1CASP1 | |
| Hydrochloric Acid SCHEMBL30765434 | 0.81 | NTRK1 (0.43) | AVPR1BF2NTRK1CMA1ELANE | |
| SCHEMBL30765911 | 0.81 | ELANE (0.40) | AVPR1BNTRK1ELANECASP1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |